AR064150A1 - Derivados antibacterianos de quinolina - Google Patents
Derivados antibacterianos de quinolinaInfo
- Publication number
- AR064150A1 AR064150A1 ARP070105443A ARP070105443A AR064150A1 AR 064150 A1 AR064150 A1 AR 064150A1 AR P070105443 A ARP070105443 A AR P070105443A AR P070105443 A ARP070105443 A AR P070105443A AR 064150 A1 AR064150 A1 AR 064150A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- mono
- aryl
- het
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Los compuestos reivindicados son utiles para el tratamiento de una infeccion bacteriana. También se reivindica una composicion que comprende un portador farmacéuticamente aceptable y, como ingrediente activo, una cantidad terapéuticamente efectiva de los compuestos reivindicados, el uso de los compuestos o composiciones reivindicadas para la elaboracion de un medicamento para el tratamiento de una infeccion bacteriana y un proceso para preparar los compuestos reivindicados. Reivindicacion 1: Un compuesto de la formula (1a) o (1b) incluyendo cualquier forma estereoquímicamente isomérica del mismo, en donde p es un entero igual a 1, 2, 3 o 4; q es un entero igual a cero, 1, 2, 3 o 4; R1 es hidrogeno, ciano, formilo, carboxilo, halo, alquenilo C2-6, alquinilo C2-6, haloalquilo, hidroxi, alquiloxi, alquiltio, alquiltioalquilo, -C=N-OR11, amino, mono o di(alquil)amino, aminoalquilo, mono o di(alquil)aminoalquilo, alquilcarbonilaminoalquilo, aminocarbonilo, mono o di(alquil)aminocarbonilo, arilalquilo, arilcarbonilo, R5aR4aNalquilo, di(aril)alquilo, arilo, R5aR4aN-, R5aR4aN-C(=O)-, o Het; R2 es hidrogeno, alquiloxi, arilo, ariloxi, hidroxi, mercapto, alquiloxialquiloxi, alquiltio, mono o di(alquil)amino, pirrolidino o un radical de la formula (2) en donde Y es CH2, O, S, NH o N-alquilo; R3 es alquilo, arilalquilo, aril-O-alquilo, aril-alquil-O-alquilo, aril-arilo, Het, Het-alquilo, Het-O-alquilo, Het-alquil-O-alquilo o un radical de la formula (3); R4 y R5 cada uno independientemente es hidrogeno; alquilo; alquiloxialquilo; arilalquilo; Het-alquilo; mono- o dialquilaminoalquilo; biciclo[2.2.1]heptilo; Het; arilo; o -C(=NH)-NH2; o R4 y R5 conjuntamente con el átomo de nitrogeno al cual ellos están unidos forman un radical seleccionado del grupo integrado por pirrolidino, piperidino, piperazino, morfolino, 4-tiomorfolino, 1,1-dioxido-tiomorfolinilo, azetidinilo, 2,3-dihidroisoindol-1-ilo, tiazolidin-3-ilo, 1,2,3,6-tetrahidropiridilo, hexahidro-1H-azepinilo, hexahidro-1H-1,4-diazepinilo, hexahidro-1,4-oxazepinilo, 1,2,3,4-tetrahidroisoquinolin-2-ilo, 2,5-diazabiciclo[2.2.1]heptilo, pirrolinilo, pirrolilo, imidazolidinilo, pirazolidinilo, 2-imidazolinilo, 2-pirazolinilo, imidazolilo, pirazolilo, triazolilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo y triazinilo, cada radical opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes, cada sustituyente independientemente seleccionado de alquilo, haloalquilo, alquilcarbonilo, halo, arilalquilo, hidroxi, alquiloxi, amino, mono o dialquilamino, aminoalquilo, mono o dialquilaminoalquilo, alquiltio, alquiltioalquilo, arilo, piridilo, pirimidinilo, piperidinilo opcionalmente sustituido con alquilo o pirrolidinilo opcionalmente sustituido con arilalquilo; R4a y R5a conjuntamente con el átomo de nitrogeno al cual ellos están unidos forman un radical seleccionado del grupo integrado por pirrolidino, piperidino, piperazino, morfolino, 4- tiomorfolino, 2,3-dihidroisoindol-1-ilo, tiazolidin-3-ilo, 1,2,3,6-tetrahidropiridilo, hexahidro-1H-azepinilo, hexahidro-1H-1,4-diazepinilo, hexahidro-1,4-oxazepinilo, 1,2,3,4-tetrahidroisoquinolin-2-ilo, pirrolinilo, pirrolilo, imidazolidinilo, pirazolidinilo, 2-imidazolinilo, 2-pirazolinilo, imidazolilo, pirazolilo, triazolilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo y triazinilo, cada radical opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes, cada sustituyente independientemente seleccionado de alquilo, haloalquilo, halo, arilalquilo, hidroxi, alquiloxi, amino, mono o dialquilamino, alquiltio, alquiltioalquilo, arilo, piridilo o pirimidinilo; R6 es arilo1 o Het; R7 es hidrogeno, halo, alquilo, arilo o Het; R8 es hidrogeno o alquilo; R9 es oxo; o R8 y R9 conjuntamente forman el radical -CH=CH-N=; R10 es hidrogeno, alquilo C1-6 o arilalquilo C1-6; R11 es hidrogeno o alquilo; Z es S o NR10; arilo es un homociclo seleccionado de fenilo, naftilo, acenaftilo o tetrahidronaftilo, estando cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes, estando cada sustituyente independientemente seleccionado de hidroxi, halo, ciano, nitro, amino, mono o dialquilamino, alquilo, alquenilo C2-6 opcionalmente sustituido con fenilo, haloalquilo, alquiloxi, haloalquiloxi, carboxilo, alquiloxicarbonilo, aminocarbonilo, morfolinilo o mono o dialquilaminocarbonilo; arilo1 es un homociclo seleccionado de fenilo, naftilo, acenaftilo o tetrahidronaftilo, estando cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes, estando cada sustituyente independientemente seleccionado de hidroxi, halo, ciano, nitro, amino, mono o dialquilamino, alquilo, haloalquilo, alquiloxi, alquiltio, haloalquiloxi, carboxilo, alquiloxicarbonilo, aminocarbonilo, morfolinilo, Het o mono o dialquilaminocarbonilo; Het es un heterociclo monocíclico seleccionado de N-fenoxipiperidiniIo, piperidinilo, pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo o piridazinilo; o un heterociclo bicíclico seleccionado de quinolinilo, quinoxalinilo, indolilo, benzimidazolilo, benzoxazolilo, benzisoxazolilo, benzotiazolilo, benzisotiazolilo, benzofuranilo, benzotienilo, 2,3-dihidrobenzo[1,4]dioxinilo o benzo[1,3]dioxolilo; estando cada heterociclo monocíclico y bicíclico opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada sustituyente independientemente seleccionado de halo, hidroxi, alquilo o alquiloxi; un N-oxido del mismo, una sal farmacéuticamente aceptable del mismo o un solvato del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125521 | 2006-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064150A1 true AR064150A1 (es) | 2009-03-18 |
Family
ID=37944337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105443A AR064150A1 (es) | 2006-12-06 | 2007-12-05 | Derivados antibacterianos de quinolina |
Country Status (30)
Country | Link |
---|---|
US (1) | US7998979B2 (es) |
EP (1) | EP2086941B1 (es) |
JP (1) | JP5356245B2 (es) |
KR (1) | KR101490221B1 (es) |
CN (1) | CN101541752B (es) |
AR (1) | AR064150A1 (es) |
AT (1) | ATE465994T1 (es) |
AU (1) | AU2007328889B2 (es) |
BR (1) | BRPI0720251B8 (es) |
CA (1) | CA2668520C (es) |
CL (1) | CL2007003516A1 (es) |
CY (1) | CY1110706T1 (es) |
DE (1) | DE602007006231D1 (es) |
DK (1) | DK2086941T3 (es) |
ES (1) | ES2344535T3 (es) |
HK (1) | HK1137428A1 (es) |
HR (1) | HRP20100384T1 (es) |
IL (1) | IL199081A (es) |
JO (1) | JO2685B1 (es) |
ME (1) | ME01073B (es) |
MX (1) | MX2009005980A (es) |
NO (1) | NO341995B1 (es) |
NZ (1) | NZ576673A (es) |
PL (1) | PL2086941T3 (es) |
PT (1) | PT2086941E (es) |
RS (1) | RS51390B (es) |
RU (1) | RU2446159C2 (es) |
SI (1) | SI2086941T1 (es) |
TW (1) | TWI412364B (es) |
WO (1) | WO2008068269A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013160431A1 (en) | 2012-04-27 | 2013-10-31 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
DK2841425T3 (en) | 2012-04-27 | 2016-06-27 | Janssen Pharmaceutica Nv | ANTIBACTERIAL QUINOLIN DERIVATIVES |
CN104650054B (zh) * | 2013-11-25 | 2019-09-13 | 重庆医药工业研究院有限责任公司 | 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物 |
WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6033389B2 (ja) * | 1979-02-22 | 1985-08-02 | 日産化学工業株式会社 | 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤 |
EP0936866A4 (en) | 1996-10-28 | 2001-04-11 | Dept Of The Army Us Government | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESIST INFECTIONS |
DK1412332T3 (da) * | 2001-07-31 | 2005-05-30 | Univ Wayne State | Quinolinderivater og anvendelse deraf som antitumormidler |
SI2301544T1 (sl) * | 2002-07-25 | 2013-01-31 | Janssen Pharmaceutica, N.V. | Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje |
EP1711492B1 (en) | 2004-01-23 | 2008-04-16 | Janssen Pharmaceutica N.V. | Substituted quinolines and their use as mycobacterial inhibitors |
DE602005016890D1 (de) * | 2004-01-23 | 2009-11-12 | Janssen Pharmaceutica Nv | Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren |
EA011572B9 (ru) | 2004-01-29 | 2018-01-31 | Янссен Фармацевтика Н.В. | Производные хинолина для применения в качестве микобактериальных ингибиторов |
MXPA06013888A (es) * | 2004-05-28 | 2007-01-26 | Janssen Pharmaceutica Nv | Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos. |
CA2579971C (en) | 2004-09-28 | 2018-02-13 | Janssen Pharmaceutica N.V. | A bacterial atp synthase binding domain |
-
2007
- 2007-11-29 JO JO2007507A patent/JO2685B1/en active
- 2007-12-04 MX MX2009005980A patent/MX2009005980A/es active IP Right Grant
- 2007-12-04 DK DK07847813.8T patent/DK2086941T3/da active
- 2007-12-04 ES ES07847813T patent/ES2344535T3/es active Active
- 2007-12-04 RS RSP-2010/0340A patent/RS51390B/en unknown
- 2007-12-04 DE DE602007006231T patent/DE602007006231D1/de active Active
- 2007-12-04 PL PL07847813T patent/PL2086941T3/pl unknown
- 2007-12-04 KR KR1020097012572A patent/KR101490221B1/ko active IP Right Grant
- 2007-12-04 RU RU2009125525/04A patent/RU2446159C2/ru active
- 2007-12-04 JP JP2009539740A patent/JP5356245B2/ja not_active Expired - Fee Related
- 2007-12-04 PT PT07847813T patent/PT2086941E/pt unknown
- 2007-12-04 CA CA2668520A patent/CA2668520C/en active Active
- 2007-12-04 US US12/516,370 patent/US7998979B2/en active Active
- 2007-12-04 CN CN2007800437666A patent/CN101541752B/zh active Active
- 2007-12-04 AU AU2007328889A patent/AU2007328889B2/en not_active Ceased
- 2007-12-04 EP EP07847813A patent/EP2086941B1/en active Active
- 2007-12-04 WO PCT/EP2007/063315 patent/WO2008068269A1/en active Application Filing
- 2007-12-04 AT AT07847813T patent/ATE465994T1/de active
- 2007-12-04 NZ NZ576673A patent/NZ576673A/en not_active IP Right Cessation
- 2007-12-04 ME MEP-2010-111A patent/ME01073B/me unknown
- 2007-12-04 SI SI200730286T patent/SI2086941T1/sl unknown
- 2007-12-04 BR BRPI0720251A patent/BRPI0720251B8/pt not_active IP Right Cessation
- 2007-12-05 TW TW096146213A patent/TWI412364B/zh not_active IP Right Cessation
- 2007-12-05 AR ARP070105443A patent/AR064150A1/es unknown
- 2007-12-05 CL CL200703516A patent/CL2007003516A1/es unknown
-
2009
- 2009-06-02 IL IL199081A patent/IL199081A/en active IP Right Grant
- 2009-07-06 NO NO20092540A patent/NO341995B1/no unknown
-
2010
- 2010-01-28 HK HK10100936.5A patent/HK1137428A1/xx not_active IP Right Cessation
- 2010-07-12 HR HR20100384T patent/HRP20100384T1/hr unknown
- 2010-07-28 CY CY20101100708T patent/CY1110706T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064151A1 (es) | Derivados de quinolina antibacterianos, composiciones farmaceuticas que los contienen y metodo de preparacion. | |
AR064153A1 (es) | Derivados de quinolina antibacterianos. procesos de obtencion y composiciones farmaceuticas. | |
RS52431B (en) | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | |
AR054889A1 (es) | Derivados de quinolina como agentes bacterianos | |
HRP20190947T1 (hr) | Heterociklički spoj | |
RU2008112290A (ru) | Производные пиридазинона, используемые для лечения боли | |
JP2010511667A5 (es) | ||
AR049127A1 (es) | Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos | |
AR064150A1 (es) | Derivados antibacterianos de quinolina | |
HRP20110540T1 (hr) | Antibakterijski derivati kinolina | |
AR051790A1 (es) | Tratamiento de tuberculosis latente | |
AR079904A1 (es) | Derivados de triazol sustituidos como moduladores de la gamma secretasa | |
AR057911A1 (es) | Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento | |
NZ626068A (en) | Multicyclic compounds and methods of use thereof | |
PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
AR080754A1 (es) | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 | |
AR078841A1 (es) | Derivados de imidazo(1,2-b) piridazina y su uso como inhibidores de pde10 | |
NZ601847A (en) | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor | |
AR054587A1 (es) | Derivados de quinolina antibacterianos | |
AR054272A1 (es) | Derivados de 3- aminopirrilidinas tri, tetra - sustituidos | |
AR052019A1 (es) | COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS | |
CO6251359A2 (es) | Compuestos de indolobenzazepina sustituida por heteroarilo | |
JP2010511671A5 (es) | ||
AR064148A1 (es) | Derivados de quinolina antibacterial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |